Table S1. Baseline patient and disease characteristics according to the setting of 90Y-RE relative to prior lines of mCRC chemotherapy.
| Parameter | 1st-line 90Y-RE (N=35) | 2nd-line 90Y-RE (N=206) | 3rd-line 90Y-RE (N=184) | 4th+ line 90Y-RE (N=158) | Unknown (N=23) |
|---|---|---|---|---|---|
| Gender, N (%) | |||||
| Female | 14 (40.0) | 74 (35.9) | 67 (36.4) | 71 (44.9) | 7 (30.4) |
| Male | 21 (60.0) | 132 (64.1) | 117 (63.6) | 87 (55.1) | 16 (69.6) |
| Age (years) | |||||
| mean ± SD (range) | 71.6±12.4 (33.6-91.9)† | 60.7±12.6 (30.0-89.2) | 61.5±12.0 (30.0-84.3) | 60.7±11.9 (33.5-88.1) | 58.5±16.9 (20.8-85.1) |
| ≥70 (%) | 21 (60.0) | 50 (24.3) | 46 (25.0) | 37 (23.4) | 6 (26.1) |
| ≥75 (%) | 17 (48.6) | 30 (14.6) | 26 (14.1) | 21 (13.3) | 3 (13.0) |
| ECOG performance status, N (%) | |||||
| 0 | 6 (50.0)xiii | 44 (61.1)xvi | 60 (65.9)xv | 57 (70.4)xiv | 1xii |
| 1 | 3 (25.0) | 25 (34.7) | 25 (27.5) | 19 (23.5) | 0 |
| 2 | 3 (25.0) | 3 (4.2) | 5 (5.5) | 3 (3.7) | 0 |
| 3 | 0 | 0 | 1 (1.1) | 2 (2.5) | 0 |
| Primary tumor in situ, N (%) | |||||
| Yes | 1 (2.9)i,§ | 35 (17.2)ii,§ | 18 (9.8)§ | 19 (12.1)i,§ | 5 (23.1)ii,§ |
| Extrahepatic metastases, N (%) | |||||
| Yes | 7 (20.0)‡ | 55 (26.7)‡ | 67 (36.4)‡ | 79 (50.0)‡ | 5 (21.7)‡ |
| Ascites, N (%) | |||||
| Yes | 1 (2.9) | 7 (3.5)iv | 8 (4.4)iv | 12 (7.9)v | 0ii |
| Controlled | 1 (2.9) | 2 (1.0) | 1 (0.6) | 1 (0.7) | 0 |
| Uncontrolled | 0 | 5 (2.5) | 7 (3.9) | 11 (7.2) | 0 |
| Prior liver-directed procedures, N (%) | |||||
| Surgery and/or ablation | 4 (11.4) | 56 (27.2) | 56 (30.4) | 50 (31.6) | 2 (8.7) |
| Vascular therapy | 0‡ | 2 (1.0)‡ | 8 (4.3)‡ | 27 (17.1)‡ | 0‡ |
| Time since identification of mCRC to RE, Median (range) (months) | 1.8 (0.4-20.9)I,‡ | 11.5 (0.9-69.3)vi,‡ | 20.1 (0.7-96.3)ix,‡ | 26.0 (4.0-90.6)ix,‡ | 8.6 (3.5-59.8)iv,‡ |
| Tumor-to-target liver ratio, median (range) (%) | 15 (0.9-71)iv | 15 (0.1-100)xi | 12 (0.3-78) x | 15 (0.2-100) x | 28 (1.7-60)i |
| Tumor-to-target liver, N (%) | |||||
| <25% | 23 (74.2)iv | 132 (70.6)xi | 126 (73.3)x | 97 (66.4)x | 10 (45.5)i |
| 25-50% | 5 (16.1) | 48 (25.7) | 43 (25.0) | 41 (28.1) | 11 (50.0) |
| >50% | 3 (9.7) | 7 (3.7) | 3 (1.7) | 8 (5.5) | 1 (0.5) |
| Albumin (g/dL) | |||||
| Median (IQR) | 3.8 (0.6) | 3.7 (0.7)vii | 3.7 (0.7)vii | 3.6 (0.8) | 3.6 (1.3) |
| CTC grade ≥1, N (%) | 9 (25.7) | 66 (33.2) | 51 (28.8) | 64 (40.5) | 9 (40.9) |
| Total bilirubin (mg/dL) | |||||
| Median (IQR) | 0.7 (0.3)§ | 0.6 (0.4)vii,§ | 0.7 (0.4)v,§ | 0.7 (0.5)§ | 0.7 (0.5)§ |
| CTC grade ≥1, N (%) | 0 | 10 (5.0) | 12 (6.7) | 13 (8.2) | 2 (9.1) |
| Alkaline phosphatase (U/L) | |||||
| Median (IQR) | 116.0 (124.0)‡ | 123.5 (111.0)viii,‡ | 147.0 (131.0)iv,‡ | 187.0 (192.0)i,‡ | 136.5 (115.0)‡ |
| CTC grade ≥1, N (%) | 17 (48.6)‡ | 96 (48.5)viii,‡ | 113 (62.8)iv,‡ | 112 (71.3)i,‡ | 13 (59.1)‡ |
| Number of 90Y-RE procedures, N (%) | |||||
| 1 | 17 (48.6) | 101 (49.0) | 83 (45.1) | 88 (55.7) | 12 (52.2)i |
| 2 | 15 (42.9) | 89 (43.2) | 88 (47.8) | 61 (38.6) | 11 (47.8) |
| 3 | 2 (5.7) | 12 (5.8) | 10 (5.4) | 5 (3.2) | 0 |
| 4 | 1 (2.9) | 3 (1.5) | 3 (1.6) | 3 (1.9) | 0 |
| 5 | 0 | 1 (0.5) | 0 | 1 (0.6) | 0 |
Missing patient baseline data on: i, 1 patient; ii, 2 patients; iii, 3 patients; iv, 4 patients; v, 5 patients; vi, 6 patients; vii, 7 patients; viii, 8 patients; ix, 9 patients; x, 12 patients; xi, 19 patients; xii, 22 patients; xiii, 23 patients; xiv, 77 patients; xv, 93 patients; xvi, 134 patients; §, P<0.05 across sub-groups; ‡, P<0.001 across sub-groups; †, P< 0.001 compared to other sub-groups.